Review

Toxicity associated with gadolinium-based contrast-enhanced examinations

Silvia Maria Lattanzio*

Department of Biomedical Sciences, University of Padua, Padua, Italy.

* Correspondence: Email: silviamaria.lattanzio@unipd.it, lattanzio.silvia.tab@gmail.com.

Abstract: This article reports known and emerging adverse health effects associated with the administration of gadolinium-based contrast agents. It focuses on the issue of the incomplete excretion of these drugs leading to the deposition of gadolinium in the tissues of the patients. The evidence of deposition is reviewed. The analysis presents gaps in our knowledge but also suggests neglected or still poorly considered parameters to possibly explain discrepancies among studies (e.g. off-label use; rate of administration; gadolinium concentration in the pharmaceutical formulation, cumulative metal toxicity). The article also presents a critical assessment of some aspects reported in the literature as well as future needs. Potential biases in the investigation and evaluation of the health/clinical implications associated with gadolinium deposition are pointed out. The analysis emphasizes that the vast majority of the clinical studies conducted up to date on gadolinium-based contrast agents were designed to assess acute toxicity and diagnostic efficacy of the agents, not to identify long-term health effects.

Keywords: gadolinium; magnetic resonance imaging; gadolinium-based contrast agents; adverse events; toxicity; gadolinium retention; gadolinium deposition

1. Introduction

Gadolinium-based contrast agents (GBCAs) are soluble metal-ligand complexes of gadolinium ion Gd^{3+}. Contrast agents fall into the definition of drugs as a tool for making a medical diagnosis [1]. GBCAs have been developed to provide additional information on pathological tissue: they increase the sensitivity and specificity of detecting and evaluating various pathologies [2], of significant relevance for discriminating cancer cells [3–6]. GBCAs are exclusively approved for use in
conjunction with a diagnostic procedure [7]. GBCAs have peculiar physical requirements as relaxation agents [3,8] and stringent biological demands for non-toxicity as pharmaceuticals and medical diagnostic tools [3]. Chelation by organic ligands is designed to protect the tissue from the interaction with Gd$^{3+}$ preventing its cellular uptake before fast excretion in the urine [9–11].

Gadolinium (Gd) is the metal sitting in the middle of the lanthanide series. Gd$^{3+}$ is well known to be toxic for living beings. Uncountable interferences of Gd$^{3+}$ in biological systems both in humans, animals, and plants are known since tens of years [12]. Toxicity of Gd$^{3+}$ in biological systems is largely caused by its ability in mimicking divalent endogenous cations, above all calcium ions (Ca$^{2+}$). It occurs not just for its ionic radius close to that of Ca$^{2+}$ but also similar coordination number, donor atom preferences, and binding behaviour [12]. The toxic potential of Gd$^{3+}$ when substituting cations such as magnesium, zinc, and iron should not be neglected as well, particularly for the role of these ions as co-enzymes in several biochemical processes in mammals [12]. Nevertheless, Gd$^{3+}$ has unique physico-chemical properties that make it the best probe to date for contrast enhanced (CE) magnetic resonance (MR) investigations for diagnostic purposes [13]. Thus, detoxification of Gd$^{3+}$ by strong organic chelators is essential for in vivo administration at dose relevant to contrast enhancement for diagnostic value [10].

Contrast agents can be classified depending on the nature of the molecular structure of the ligand: linear (i.e., open-chain molecule) or macrocyclic (i.e., cyclic ligand) and ionic (i.e., dissociation into charged particles occurs in solution) or non-ionic [10]. Different chelating molecules have been developed and introduced in clinical practice since the eighties [11]. The pharmaceutical chelate determines the pharmaco-kinetic of the agent and in vivo distribution [3,11].

2. Known adverse drug reactions of GBCAs

Despite the excellent safety profiles of GBCA respect to other contrast agents (e.g., iodinated contrast agents), adverse drug reactions (ADRs) occur. The rate of known acute ADRs associated with gadolinium-based contrast agent (GBCA) administration has been estimated to range from 0.07% to 2.4% [14]. The primary sorting is between those anaphylactic [15–18] and non-anaphylactic in origin [19] and renal and non-renal [10,20–26].

2.1. Non-renal acute and severe ADRs

Anaphylactic reactions are rare adverse drug reactions (ADRs) [16]. Few reports of anaphylactic ADRs of GBCAs have been published [17,18]. Anaphylactic reactions are difficult to predict [27] unless a previous reaction to the same agent has already occurred [18]. They are usually fast up to immediate and can lead up to very fast fatal outcomes [17,18].

2.2. Acute mild ADRs

Acute local (ADRs) have a much more favourable prognosis. Most common acute mild ADRs are emesis, nausea, headaches or local reactions at the site of injection. The last ones comprise local necrosis, edema, and inflammation [28] mainly due to contrast extravasation into tissues [10,20,21], erythema, swelling, pain at and proximal to that site: they typically occur early, within few days after administration, they peak and resolve over some days [28]. Delayed-onset cases of ADRs are also
known. Varied gastrointestinal, neurological, respiratory, dermatological, cardiovascular, and more generalized non-specific adverse reactions have been reported [28].

2.3. Nephrogenic systemic fibrosis

The main known acute renal adverse reaction of GBCAs is nephrogenic systemic fibrosis (NSF), yet cases with delayed onset had been reported [29–31]. NSF is a painful fibrosing disorder associated with impaired excretion of GBCAs in subjects with kidney diseases. It is chronic, often progressive, and even life-threatening [32–35]. Historically, symptoms associated with inefficient excretion of GBCAs were initially recognized in patients with renal impairment, described as a unique cutaneous fibrosis disorder named nephrogenic fibrosing dermopathy (NFD) [36]. The first case was diagnosed in 1997 and published in 2000 [37]. It was characterized by cutaneous changes, “indurated plaques and papules” mainly on the extremities, “thickening and hardening of the skin associated with brawny hyperpigmentation”. A unique histopathological finding emerged [36]. When extra-cutaneous fibrosis was observed, it led to the definition of a new clinical condition termed NSF [32,36]. NSF is early characterized by progressive skin thickening, tethering, pain, swelling and skin lesions often pruritic [32,38]. Patients often develop joint stiffness and contractures, muscle weakness and deep bone pain [38]. Epidermal atrophy, follicular dimpling (peau d'orange), hair loss, mild to moderate edema are also reported often later in the course [32,39]. Radiographic images show abnormalities other than skin alterations in NSF confirmed biopsy patients—but described as non-specific alterations [38,40]. Acute kidney injury, chronic kidney diseases, end-stage renal failure, and glomerular filtration rate (GFR) or estimated GFR below 30 ml/ min/ 1.73 m$^2$ are considered as the main risk factors [35,41]. Additional risk factors include “pro-inflammatory events” at time of GBCAs administration (including surgery), epoetin use, acidosis, hyperphosphatemia [39], liver dysfunction [42,43], high doses and multiple administrations [34,39,44]. Yet, NSF cases with biopsy confirmation have been reported in subjects who received a single dose [38,41].

Still the pathophysiology of NSF is not fully understood, and it lacks a cure. The presence of gadolinium seemed to drive fibrosis in the context of renal dysfunction, thus NSF has been proposed to be renamed “gadolinium-associated systemic fibrosis” (GASF) to better reflect the pathogenesis of the disease, being the term “nephrogenic” misleading [45,46].

The stability of Gd$^{3+}$-complexes has been correlated with the likelihood of releasing gadolinium ions in vivo [47] and inducing fibrosis [32]. The linear agents have been categorized as more likely to predispose to the development of NSF [32]. The pharmaceutical formulation of the agents has been also considered, and the lesser quantity of added free ligand has been associated with higher incidence of NSF [48]. Conversely, the excess free ligand (or sodium or calcium salt complexes) enhances the probability of chelating endogenous cations and thus the probability of leading to retention of pharmaceutical chelates complexed with ions other than Gd$^{3+}$ [48].

The manifestation of NFS opened several questions on the real in vivo safety and stability of GBCAs. Concern on gadolinium retention in humans openly emerged for the first time and led to regulatory updates (i.e., first call for box warnings in 2007 [49]). Revisions of the procedure guidelines, restriction of their use in patients with renal diseases, and best practice recommendations [50,51] highly decreased the incidence of NSF [52,53]. Guidelines recommend careful evaluation of each case, balancing benefits, risks, and disadvantages. Whilst anaphylactic reactions are very rare and often difficult to be prevented, judicious approach to the administration of GBCAs in patients with
underlying kidney diseases appears the most effective strategy to prevent NSF [35].

3. **Gadolinium deposition**

3.1. **Gadolinium deposition within brain**

Novel toxicity issues were raised when the evidence of incomplete excretion was reported in subjects with normal renal function. Gadolinium deposition has been early investigated in biopsies of brain tumours by Xia and colleagues in 2010 [54]. They found insoluble deposit containing gadolinium associated with phosphorus and calcium, particularly in specimens from patients who received multiple administrations of GBCAs. In 2013, deposits were measured in autoptic brain samples by Kanda et al. [55]. Abnormal hyperintensity in non-enhanced MRI images was detected in the dentate nucleus of the cerebellum and in the globus pallidus and were associated with gadolinium deposits confirmed by analysis of autoptic brain specimens. In 2015, McDonald et al. reported similar results in several brain structures, suggesting widespread accumulation of gadolinium in the brain parenchyma and correlation between administered dose and signal intensity enhancement [56]. Since 2015, a great number of studies has been performed to assess gadolinium deposition [57–59]. The bulk of literature data reported gadolinium deposition as associated with the administration of linear agents both in humans (adult and paediatric patients) [60–73] and in animals [74–79]. Imaging studies with macrocyclic agents often have not shown marked abnormal hyperintensity in specific brain areas and this evidence led to state the absence of gadolinium deposition [80–85]. Nevertheless, evidence of deposition associated with the administration of macrocyclic agents exists [86–91]. Brain deposits have been measured even in the absence of hyperintensity [92].

In summary, deposition associated with linear agents is a tenet, whilst deposition associated with macrocyclic agents remains more debated. Yet, even a single dose of a macrocyclic agent has recently caused detectable gadolinium deposits in the human brain tissues measured in autoptic samples [86].

3.2. **Gadolinium deposition within bone and hair**

Major attention on gadolinium deposition in humans has been paid to the brain, despite initial evidence of deposition was earlier reported in the bone. Gadolinium deposits in femoral heads of patients who underwent total hip arthroplasty were investigated *ex vivo* by Gibby et al. [93] in 2004 and by White et al. in 2006 [94]. Few years later, a similar cohort of patients was the object of investigation by Darrah and co-workers [95], who measured high gadolinium levels years after the exposure to GBCAs. In 2016, Murata and colleagues [96] measured gadolinium deposits both in bone and brain tissues of patients receiving GBCAs. Albeit the number of administrations and time distances from administrations and analysis were highly variable among cases considered, bone median levels were significantly (i.e., up to 23 times) higher than the already abnormal brain levels. In 2018, Lord et al. [97] measured deposition of gadolinium in the bone *in vivo* in apparently healthy volunteers and demonstrated that gadolinium can be retained and detected in bone after a single dose. More recently, Turyanskaia and colleagues [98] detected and mapped gadolinium accumulation in a bone biopsy of a male patient with idiopathic osteoporosis: Gadolinium distribution occurred in cortical bone tissue and correlated with other detected elements, as calcium and zinc. Gadolinium
deposition in the skeleton has the potential for systemic adverse effects impacting on body homoeostasis [95]. Like other lanthanides, the biological half-life of gadolinium in the bone has been reported for almost two decades, depending on animal species under consideration [99]. Delayed mobilization of gadolinium from bone stores during the process of bone remodelling carries the possibility of delayed and long-term adverse effects [95]. Methods of analysis based on radiation physics in vivo might be helpful to investigate the real incidence and prevalence of gadolinium deposition, of particular interest concerning the bone [100]. Yet, hair and nail analysis might be even a better tool for accessing metal deposition, because fully non-invasive. Hasegawa et al. [101] have recently published evidence of gadolinium in hair using laser ablation inductively coupled plasma mass spectrometry. The study found significant correlation between hair and brain gadolinium concentrations, especially in white matter and dentate nucleus among decedents who received GBCAs. Despite the small number of subjects involved in the pilot study, the results are very promising. Hair analysis might be a reliable method to noninvasively sampling, quantifying, and monitoring gadolinium (and other lanthanides) in vivo in humans. The technique is also relevant to investigate the time dynamics of deposition and delayed wash out. Considering that the concentrations of metals in hair are usually order of magnitude higher than in the blood and urine [101], it can be a very attractive tool for buoying gadolinium deposition and associated possible chronic and sub-chronic toxicity, also abating false-negative results from delayed blood or urine examinations. Fingernail analysis has also been used to demonstrate gadolinium intoxication [102].

3.3. Market restrictions and possible unrecognised adverse health effects

In 2015 U.S. Food and Drug Administration (FDA) published the first drug safety communication on gadolinium deposition, yet without recognizing any associated disease [103]. Regulatory actions by the European Medicines Agency (EMA) acknowledged the evidence of deposition associated with linear agents in 2017. EMA embraced a precautionary position in patient's safeguard: Restrictions and suspensions of marketing authorizations have been implemented in Europe [104]. EMA suspended the use of most linear agents [104]. But only few other regulatory authorities followed a similar approach, mainly in the Middle East (i.e.; United Arab Emirates, Jordan and Kingdom of Saudi Arabia) [105]. Variably updating of package insert and recommendations have been required in the rest of the world [105]. The Pharmaceuticals and Medical Devices Agency restricted linear agents to second line agents in Japan and asked for revision of the precaution indications [106,107]. Conversely, all the nine GBCAs still maintain the marketing authorization in the rest of the world [105], and this position reflects that of the U.S. Food and Drug Administration [7,105] and the American College of Radiology [108]. In 2017, they recognized the occurrence of deposits in humans, but they found no evidence of harm for patients [108]. Notwithstanding, new class warning have/should have been introduced updating the prescribing information, requirements, and prescriber/dispenser actions asking for advising patients that “gadolinium is retained for months or years in brain, bone, skin, and other organs in patients with normal renal function”[109]. And “the clinical consequences of retention are unknown” [109]. This warning update also pro-actively disentangles industrial producers and physicians from litigations that are growing in the U.S. [110]. In 2016, Semelka et al. published a collection of cases reporting symptoms following GBCA administration in patients with normal renal function [111]. It was the first hint of a still unrecognised clinical condition of a possible systemic gadolinium toxicity. The
term **gadolinium storage condition** was initially coined to define the condition with no excretion and no symptoms, where the gadolinium is supposed to lie “primarily inert within the body”. A symptomatic condition where gadolinium is not inert was termed **gadolinium deposition disease** by Semelka and colleagues, thus highlighting a possible new clinical entity [112]. A survey of patients with chronic symptoms following GBCA administration was published the same year and data from FDA Adverse Reporting Symptoms [113]: The self-reported symptoms spanned from musculo-skeletal ones, such as bone and joint pain, joint contracture, burning and sharp pain in the torso, legs, and arms to fatigue, flu-like aches, paraesthesia, headaches, cloud mentation, diminished memory and skin changes. Gadolinium containing deposits were also variably reported in urine, hair, and skin of the patients in the survey [114,115]. The same year, Roberts et al. reported severe joint contracture of unknown aetiology in a brain cancer patient who had gadolinium deposits in the skin and showed marked signs of gadolinium deposition in the cerebellum after a large number of GBCAs administrations [116].

High signal intensity in the DN and GP on unenhanced T1-weighted MR images was reported also in patients with impaired renal function by Barbieri et al. [117]. And of note, the authors reported that all three patients object of the study suffered from “transient sign of neurological disorders of undetermined cause” [117]. Similar unexplained clinical observations have been reported by Swaminathan [118], who referred to “several patients with normal renal function and significant residual gadolinium who manifest new-onset unexplained extremity pain (neuralgic type) and stiffness without any definite evidence of NSF after exposure to GBCAs”. In 2020, it has been published a case reporting signs of gadolinium deposition in the brain and a causal role for gadolinium in the aetiology of the symptoms experienced by the patient after multiple administrations of a macrocyclic contrast agent in the contest of normal renal function [91].

### 3.4. Investigating the mechanisms of gadolinium deposition

The biophysical mechanisms that govern deposition and associated toxicity are not fully understood. The role of short-term dechelation of linear Gd$^{3+}$-complexes might be only the simplest part of the toxicity, since retention of the intact complexes has been reported [79,116,119–121]. Receptor-mediated endocytosis of chelated gadolinium has been also observed [122]. Intact complexes carry toxicity issues not only due to the possible delayed mobilization of gadolinium, but also by their-own, without dechelation to occur. Early in the 1980s, Lauffer reported that chelate toxicity includes alteration of membrane potentials, enzyme inhibition, or nonspecific protein conformational effects [3]. A recent study by Kartamihardja et al. [121] in mice demonstrated that gadolinium may be distributed throughout the brain tissue in chelated form, possibly via the choroid plexus. Bonding of intact complexes to macromolecules has been also demonstrated and deposits have been variably found in rats in different forms including, in addition to intact complexes, soluble small molecules, soluble macromolecules, and insoluble species [123]. Gadolinium accumulation within the cerebro-spinal fluid has been reported in humans, even in the setting of normal renal function and without blood-brain-barrier dysfunction [124]. It has been also recently proved that intact complexes can be internalized by leukocytes and erythrocytes. Despite the large majority of the complexes remaining in plasma, GBCAs seem to be able to cross the membrane of blood cells and be internalized by diffusion or, possibly, by pinocytosis [119]. Other studies by Di Gregorio and colleagues in animal models support the view that the majority of gadolinium retained in the brain arises...
from intact complexes that have extravasated immediately after the intravenous administration [120]. The internalization of more stable complexes might be of long-term impact by delayed dissociation.

It is still unclear which gadolinium-containing species (Gd-species) is producing T1-shortening associated with gadolinium deposit in imaging data [125]. The term “species” and “speciation” refer to the chemical form of the deposits containing gadolinium [126]. It has been hypothesized that insoluble gadolinium-species are not responsible for T1-signal enhancement [74]. Retained gadolinium in the brain tissue may be bound to organic molecules, including proteins [121]. Both soluble and insoluble species have been detected [74,116], but a speciation analysis of the deposits is often absent or it is intrinsically hampered by the low concentration of deposits, methods of analysis or sample treatment [120,127] (e.g.; nitric acid digestion [95] or wash out of soluble entities [75]). Also, a detection limit exists not only in imaging analysis but also in quantification studies and it may vary from different techniques and instruments: In a recent study performed on a large animal model it has been reported that the quantitative analysis had a limit of 5.7 ng gadolinium/g tissue, while it was reported that gadolinium becomes visible in MRI if a threshold of approximately 1 µg gadolinium/g of tissue is exceeded [76]. It has been speculated that different degrees of angiogenesis and potential microleaks may result in visually undetectable gadolinium on conventional T1-weighted MRI due to low gadolinium concentration [128]. Imaging studies reporting negative results may confirm lack of signal enhancement, but not lack of gadolinium deposits. The case study by Roberts and colleagues quintessentially lends support to the relevance of this situation: gadolinium deposits have been found in autoptic brain samples in the absence of any hyperintense signal in magnetic resonance images [92]. Similarly, Kiviniemi and colleagues detected gadolinium deposits in glioma specimens and in adjacent normal brain tissue that showed no evident contrast enhancement on T1-weighted MR images [128]. The hypothesis of a widespread deposition in the brain parenchyma has been supported by previous evidence on human brain autoptic samples [56,129]. The role of tissue density might be also important to produce a detectable hyperintense signal from deposits and it might explain the reason why hyperintensity in the cerebellum has been earlier noted. The cerebellum has high cell density [130] and it is a major repository of metals [131]. The dentate nucleus is particularly rich in copper localized to the periphery, whilst iron and zinc are abundant centrally [131].

3.5. Delayed manifestation of gadolinium toxicity: the lack of evidence and the evidence of absence

The most urgent gap to fill concerns the existence of health effects associated with gadolinium deposition. A definitive consensus still lacks and international research efforts are ongoing [125]. To the best of our knowledge, a single epidemiological retrospective imaging study in healthy volunteers who underwent whole-body MRI have been published. The study, supported by the industrial producer of the agent, was published in 2017 based on data ranging from 2008 to 2012 [132]. It failed to find a difference in relative signal intensities of selected brain structures 5 years after a single administration of a 1.5-fold the minimal standard dose of the macrocyclic gadolinium complex gadobutrol; i.e., 0.15 mmol/kg (the concentration of the gadolinium is not reported in the paper but in the past gadobutrol was available at two different concentrations, 1M or 0.5 M concentration [133]). It can be concluded that the administration of the above mentioned dose and agent in healthy subjects does not cause hyperintensity in specific brain regions 5 years after administration.

The main argument of those who deny harm associated with gadolinium deposition is the lack
of clinical evidence. But at least two considerations can be done against this belief and to support the thesis that long-term studies are needed to draw final conclusions:

(i) the most of the imaging studies designed to investigate gadolinium deposition aimed to elucidate an imaging finding, and not its clinical significance. These studies investigated the existence of abnormal hyperintensity in the brain, not its clinical significance, as explicitly declared in the aims of the study [67];

(ii) the majority of the studies conducted up to date on GBCAs were designed to access acute toxicity and to investigate diagnostic efficacy of the agents, not to identify long-term health effects. Indeed they had short time follow-ups. The investigation of the onset of adverse reactions occurred within few days after the administration of GBCAs. This period of time allow to assess the acute toxicity. Examples among the recent ones are: 72 hours after GBCA administration in the phase III study by Gutierrez et al. [134]; 24 ± 4 hours after GBCA administration in the phase III study by Kuwatsuru et al. [135]; 24 hours after GBCA administration in the study by Liang et al. [136]; time window not reported, but clinical outcomes were limited to renal function before and after administration and occurrence of contrast-induced-nephropathy in the study by Naito et al. [137]; time window not reported in the study by Semelka et al., but clinical outcomes were acute, visually apparent adverse events [138]; 72 hours after GBCA administration in the study by Tanaka et al. [139]; time window not reported in the phase III study by Zech et al. [140]. Long-term adverse effects are intrinsically overlooked if the study follow-up is restricted to a few days. The issue of chronic toxicity has been mainly evaded, despite (i) more than 30 years of clinical use and despite (ii) the evidence of gadolinium deposition in bone, liver, kidney of rodents after exposure to linear agents has been known since the 1990s [128,141]. However, the risk of potential accumulation of gadolinium in humans had been taken into a possible scenario, but poorly considered at that time as believed “unlikely [GBCAs] to be administered repeatedly in patients” [142]. But, repeated administrations have become a reality in several cohorts of patients, like long-term cancer survival, multiple sclerosis patients or subjects with chronic pathologies. Concerns were also explicitly pointed out by Shellock and Kanal in 1999 regarding the accumulation of the MR imaging contrast agents after multiple doses administered to patients: Despite they pointed out the lack of data regarding the safety of long-term cumulative exposure to low doses of free gadolinium ion and the need of further investigations, the hypothesis of “a clinical limitation to the number of times a patient can be safely scanned with gadolinium-based contrast agents” was elicited [28]. Some studies in animal models and one in pregnant women showed some possibilities of long-term gadolinium toxicity. Khairinisa et al. examined the effects of perinatal exposure to GBCAs on the behaviour of adulthood offspring and showed that gadolinium can be transferred to pups and was retained in their brain during postnatal development. This occurrence may lead to impaired brain development and affect motor coordination, memory task, tactile sensitivity and cause anxiety-like behaviour [143]. Ray et al. investigated toxicity associated with GBCAs in humans and found that gadolinium at any time during pregnancy was associated with an increased risk of a broad set of rheumatologic, inflammatory, or infiltrative skin conditions and for stillbirth or neonatal death [144]. Investigations in animal models by Runge et al. reported sub-chronic toxicity of the GBCAs, i.e. the potential for premature loss of ovarian function [145].

More recently, gadolinium deposits have been reported in the spinal cord and peripheral nerves in rats exposed to multiple administrations of linear and macrocyclic contrast agents [146]. No hippocampal neurogenesis or altered spatial working memory performance have been observed from
animal tests, but heat and mechanical hyperalgesia has been associated with the linear agents. The authors hypothesize the sensitization of spinal cord nociceptive neurons and that gadolinium in the spinal cord and peripheral nerves might contribute to sensory symptoms and burning pain in the torso and extremities described by some patients [146].

4. Remarks on known and still poorly considered parameters playing a role in deposition

Reduced renal function and liability to dechelation and transmetallation have been recognized as the main responsible for gadolinium deposition in the tissues. Yet, deposition of intact complexes occurs. The role of transporter proteins and binding to macromolecules has been investigated and showed that GBCAs are able to penetrate a series of brain barriers [121]. Repeated administrations increase the risk of deposition and several studies showed that a dose-dependent relationship exists between the number of GBCA administrations and the amount of gadolinium deposits [56,89,90,62,85]. Inflammation has been shown to facilitate gadolinium retention into brain tissue [147]. Animal studies investigating the involvement of the glymphatic system activity suggested a role played by anaesthesia, sleep, and morning administration to facilitate the glymphatic clearance in rat brain [123].

Table 1. Parameters that play or might play a role in gadolinium retention/toxicity.

| Types of parameters | Parameters and conditions |
|---------------------|---------------------------|
| Known [9,95]        | - Thermodynamic and kinetic stability of the agent  |
|                     | - availability of the potential transmetallation partners |
|                     | - administered dose (single high level exposure) |
| to further/better evaluate [123,126,147] | - cumulative dose |
|                     | - low-level cumulative storage |
|                     | - distance among subsequent administrations |
|                     | - medications (eg; epoetin, glucocorticosteroids,...) |
|                     | - inflammation, pro-inflammatory events, acidosis, hyperphosphatemia, and liver dysfunction |
|                     | - co-exposure to high intensity static magnetic field, time-varying magnetic field gradients, and radio frequencies during examinations |
|                     | - role of anaesthesia |
|                     | - dose conversion from animals to humans |
|                     | - protein binding |
|                     | - intact pharmaceutical complexes (i.e.; without dechelation to occur) |
|                     | - metabolic conditions (e.g.; diabetes, fasting, ...) |
| Suggested to investigate | - rate of administration |
|                     | - gadolinium concentration in the pharmaceutical formulation |
|                     | - gender (e.g.; relevance for dosing, susceptibility to toxicity, role of hormones) |
|                     | - intra-individual analysis |
|                     | - implants and prostheses |
|                     | - rare earths present as impurities in the agents |
Here, other parameters that might play a role are suggested to be considered in future studies:

i. The rate of administration and the concentration of gadolinium in the pharmaceutical formulation of the agents.

ii. The time interval among subsequent administrations and the cumulative dose.

iii. The gender differences;

iv. Co-exposure to high intensity static magnetic field, time-varying magnetic field gradients, and radio frequencies during examinations.

v. Toxicity rising from deposits of other lanthanides present as impurities in the GBCAs.

vi. The presence of an exogenous compound in the patient's body (e.g., prostheses or implants, particularly breast implants).

Known and suggested parameters are listed in table 1.

4.1. Off-label use

A faulting mix might occur in the setting of the off-label use of GBCAs. Off-label use can be related to unapproved indication, dose, dosing schedule or rate and route of administration of GBCAs [148]. Approval of contrast agents officially follows the same avenue of drugs with therapeutic effects [148]. GBCAs are approved for specific body indications and applications [7], the label is guidance for use with information on the dose and indications [148]. Anyway, off-label use is routinely practised at imaging centers [1,7,149]. The adverse potential of this practice has been somehow underestimated. As early, as 2008, Reimer and Vosschenrich observed how many agents were not approved for the current spectrum of their clinical applications [148]. Also, the financial burden associated with the approval has been pointed out [148]. Again, Tamburrini and colleagues in 2011 highlighted poor investigation of the off-label use of contrast media, in particular, deviations from recommended dose that commonly, but not exclusively, applied to magnetic resonance angiography as well as cardiac and paediatric applications [1]. Repeated high-dose administration might trigger dose-related adverse reactions and metabolic abnormalities: Wolansky et al. reported that serial administration of triple-doses of GBCAs was associated with hypophosphatemia in a cohort of multiple sclerosis patients [150].

4.2. Rate of administration

The rate of administration might be one of the neglected parameters able to explain the dissociation of complexes with recognized higher stability (i.e.; macrocyclic agents), but also the condition able to exacerbate the liability of the linear complexes. The injection rate should be reported in each study, yet literature contributions often lack specifying the injection rate. Recommended injection rate is 2-3 ml/s (0.5 mmol/ml) [11]. However, there are specific studies that are known to require higher rates and high doses and/or higher concentrations of the agent to enable the acquisition of an adequate signal. It is the case of cerebral perfusion studies wherein a robust and compact bolus arrival in the cerebral tissue is required [149,151]. Automated injection is also required [151]. In these requirements, the injection rate reaches 5 ml/s, that is the double of the mean standard rate of delivery, and often it is combined with agents formulated at high concentration (i.e., Gadovist 1.0 mmol/ml gadobutrol). Lacking to report the concentration in literature contributions can create biases in the evaluation and comparison of different studies when there exist agents available
at different formulations. It is the case of gadobutrol formulated as Gadovist 1.0 mmol/ml or 0.5 mmol/ml, reported in the past [11]. For instance, Lee and colleagues [152] reported perfusion performed with Dotarem 0.5 M (gadoterate meglumine). The authors report a standard single dose of 13 ml and double dose for perfusion studies: It follows that the dose is not proportional to body weight as it is in most studies and protocols. Lin and Brown [9] reported injection rate up to 5 ml/s for cerebral perfusion studies at their own institution in 2008 and high dose (up to 0.3–0.4 mmol/kg) at concentration 0.5 M.

The same injection rate referred to a medium formulated at a double concentration means a double amount of gadolinium injected in the body per second. Even if the total dose of the gadolinium administered is the same, the two conditions are different. (To making this note clearer, this is a numerical example: a double minimum standard dose (i.e.: 0.2 mmol Gd/kg body weight) of a low-concentration agent (such as macrocyclic Dotarem 0.5 mmol/ml) means a total administered volume of 0.4 ml/kg body weight; the same dose of an agent formulated at higher (double) concentration, such as gadobutrol 1.0 mmol Gd/ml, means a half total volume administered, that is 0.2 ml/kg body weight. In the former case the standard flow rate of 2–3 ml/s means 1–1.5 mmol Gd/s, while 2–3 mmol Gd/s in the latter. But, in the case of the administration at higher rate, 5 ml/s, 2.5 mmol Gd/s are administered in case of low-formulation at 0.5 mmol Gd/ml and 5 mmol Gd/s in the case of high-concentration (i.e.; 1 mmol/ml).)

4.3. Study design, risk factors and the evaluation of a possible individual susceptibility

Individual susceptibility to deposition might markedly vary among subjects. A recent study on gadolinium deposition in a large animal model has shown significative inter-subject variability: a double concentration of gadolinium has been retained in the cerebellum of one sheep with respect to another (58, 76, 116 ng x g⁻¹) even after a single injection of 0.1 mmol/kg of a linear complex, a dose comparable to that for a human patient [76]. These differences might be poorly understood just assessing mean values. The publication of raw data in parallel with mean values and processed data might be useful to unravel still unknown parameters of relevance.

The number of administrations, the time distances among them, and the time distance from the last administration are crucial parameters in the evaluation of gadolinium deposition and must be taken into account in the study design and data analysis. Since gadolinium deposition appears to be a complex process of still not known dynamics (i.e.; evolving over time in an unknown balance among retention and possible delayed excretion), it cannot be fruitfully understood in humans in the singularity of a time-point measurement. The evolution over a period of time should be considered, not just a comparison of the imaging data at the first and last time point.

4.4. Electro-magnetic field exposure, time-varying magnetic field gradient in conjunction with high intensity static magnetic field

The context for challenging adverse reactions possibly associated with GBCAs (and their long-term effects in humans) should not be confined to GBCA administration alone (as often addressed in animal studies and phase I studies). The whole context comprises GBCA administration in conjunction with exposure to electromagnetic fields in the clinic (i.e.; the application of radio-frequencies sequences and time-varying magnetic field gradients in the presence of high
intensity static magnetic field soon after injection of GBCAs [153]). The whole topic is “toxicity associated with gadolinium-based contrast enhanced examinations" not only “GBCA administration". Cho et al. showed that exposure to electromagnetic fields adds gadolinium-associated cytotoxicity and genotoxicity to toxicity of gadolinium alone [154]. In turn, the specific condition of GBCA administration in subjects who already have gadolinium in their tissues should be taken into account. Also, the role and impact of increasing electromagnetic fields exposure in normal life should be included in the evaluation of delayed adverse effects associated with gadolinium retention in the body.

4.5. Metal toxicity as a whole and threshold for symptom onset

Even though it is easier to measure metal concentrations in animals, elucidating the clinical manifestations in animal models can be more challenging [155]. Furthermore, the issue of metal toxicity in animals may be not reflective with regard to the actual exposure in humans that are simultaneously exposed to more than one metal coming from the environment, its contamination by anthropogenic activities, drug exposure [155], and the presence of prostheses or metal dental restorative materials. The effects of the combination of different metals potentially toxic may be of clinical relevance, despite the concentration of each one being estimated irrelevant.

Combined chronic or long-term effects are more difficult to disentangle, particularly when no single high-level exposure or acute reaction occur, but cumulative storage. As mentioned above, on-going inflammation facilitates gadolinium retention into brain tissue [147], as a consequence, the data from healthy animal models possibly underestimate the deposition in human patients. Manifestation of toxicity depends from the amount, speciation of deposits, and compartment where they are stored. Retention of a small percentage following the administration of a single standard dose may be too low to induce any observable clinical manifestation. This might partially explain the lack of reported symptoms in studies showing deposits in healthy volunteers, such as those by Lord et al. [97]. The issue of cumulative administrations has been already pointed out, but not specific guideline or time schedule have been published, such as an inferior limit for subsequent administration: FDA recommended minimizing “repeated GBCA imaging studies when possible" and “particularly closely spaced MRI studies”. However, the recommendation was also to “not avoid or defer necessary GBCA MRI scans" [156]. Nevertheless, it is at the same time important that the patient is really aware of the possible risks and benefits of the proposed treatment through the information provided by the physician when obtaining written informed consent [1].

Veiga et al. [157] measured rare earth (RE) impurities in commercial GBCAs: they found RE as impurities in all the samples analysed. The levels varied among both the elements and the agents and the differences can be considerable. The concentrations are higher for elements close to Gd, i.e. Eu and Tb, but also for La in Gavovist and Viewgam. Lanthanum impurities might be of relevance particularly for deposition in the bone [120]. Toxicity rising from deposits of other lanthanides present as impurities in the GBCAs deserves to be taken into consideration.

4.6. Gender differences

The issue of gender deserves specific attention, involving hormonal issues and also the dose. Females seem to be more exposed to adverse effects associated with gadolinium deposition [112]: it
should be understood if this is correlated to a higher retention or not. The issue of administered doses—based on body weight—individually from the gender that is only indirectly considered thanks to the gender correction in the evaluation of estimated GFR from blood creatinine (i.e., factor 0.8 [15])—merits to be better evaluated to understand if a risk of overdosage exists in women. The ratio among muscle mass and fat mass—possibly assessed in the practice by body mass-index (BMI)—might be also better considered. Khairinisa [143] showed higher total gadolinium concentration in female mice, although behavioral alterations were not always more severe in females. Increasing evidence shows that health effects of some toxic metals differently manifest in male and female [45]. It is increasingly important to take account gender differences when evaluating toxic insults.

4.7. Clinical and environmental exposure

GBCAs are exclusively approved for use in conjunction with a diagnostic procedure [7]: primarily, nuclear magnetic resonance examinations - taking advantage from the relaxation effect of Gd³⁺ [8]. But, it is worth to recall that prior to the recognition of NSF, GBCAs have been also used in conjunction with computed tomography (CT) as an alternative agent to iodinated contrast media in patients with impaired renal function or in patients with iodine allergy—taking advantage from the X-ray absorption properties of Gd³⁺[159]. This practice enlarges the cohort of patients that could have been administered with GBCAs in their clinical history and, in turn, to be considered when investigating long-term effects associated with GBCA administration. Moreover, the growing environmental contamination with anthropogenic gadolinium from GBCAs [160–162] opens healthy issues in healthy subjects of worldwide population and live-beings. The impact of these compounds has been already showed worrying effects on marine wildlife [163–166]. Contamination of water and soil and penetration into human and animal food chain are a concerning reality [160,161,167].

5. Summary and conclusion

Known and emerging adverse reactions associated with administration of GBCAs have been reported. GBCAs are a staple of medical radiology with a good safety profile with respect to other contrast agents. Nevertheless, the evidence of gadolinium deposition has opened a vivid debate on possible still unrecognized adverse effects of these drugs, particularly those long-term. A great number of studies has been already showed worrying effects on marine wildlife [163–166]. Contamination of water and soil and penetration into human and animal food chain is a concerning reality [160,161,167].

The physico-chemical mechanisms involved in the process of deposition have not been fully elucidated. Yet, the most urgent gap to fill concerns the existence of clinical/health implications. A rich research road-map is ongoing. Still, the consensus lacks as much as longitudinal studies, but initial evidence of health effects has been published. Here, we have presented a critical analysis pointing out biases to overcome. Also, we have explored parameters that are still poorly considered that deserve further investigations. Disentangling and recognizing the pathological potential of gadolinium-associated toxicity is of primary relevance in patients.
Conflict of interest

The authors declare no conflict of interest.

References

1. Tamburrini O, Aprile I, Falcone C, et al. (2011) Off-label use of intravascular iodinated organic and MR contrast media. Radiol Med 116: 1–14.
2. Meloni MM, Barton S, Xu L, et al. (2017) Contrast agents for cardiovascular magnetic resonance imaging: an overview. J Mater Chem B 5: 5714–5725.
3. Lauffer RB (1987) Paramagnetic metal complexes as water proton relaxation agents for NMR imaging: theory and design. Chem Rev 87: 901–927.
4. Schörner W, Kazner E, Laniado M, et al. (1984) Magnetic resonance tomography (MRT) of intracranial tumours: Initial experience with the use of the contrast medium gadolinium-DTPA. Neurosurg Rev 7: 303–312.
5. Essig M, Anzalone N, Combs SE, et al. (2012) MR imaging of neoplastic central nervous system lesions: review and recommendations for current practice. Am J Neuroradiol 33: 803–817.
6. Anzalone N, Gerevini S, Scotti R, et al. (2009) Detection of cerebral metastases on magnetic resonance imaging: intraindividual comparison of gadobutrol with gadopentetate dimeglumine. Acta Radiol 50: 933–940.
7. Malayeri AA, Brooks KM, Bryant LH, et al. (2016) National Institutes of health perspective on reports of gadolinium deposition in the brain. J Am Coll Radiol 13: 237–241.
8. Weinmann HJ, Brasch RC, Press WR, et al. (1984) Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent. Am J Roentgenol 142: 619–624.
9. Lin SP, Brown JJ (2007) MR contrast agents: Physical and pharmacologic basics. J Magn Reson Imaging 25: 884–899.
10. Ersoy H, Rybicki FJ (2007) Biochemical safety profiles of gadolinium-based extracellular contrast agents and nephrogenic systemic fibrosis. J Magn Reson Imaging 26: 1190–1197.
11. Bellin MF, Van Der Molen AJ (2008) Extracellular gadolinium-based contrast media: an overview. Eur J Radiol 66: 160–167.
12. Evans CH (1990) Biochemistry of the Lanthanides, New York: Plenum Press.
13. De León-Rodríguez LM, Martins AF, Pinho MC, et al. (2015) Basic MR relaxation mechanisms and contrast agent design. J Magn Reson Imaging 42: 545–565.
14. Levine D, McDonald RJ, Kressel HY (2018) Gadolinium retention after contrast-enhanced MRI. JAMA 320: 1853–1854.
15. Shepherd M, Lata S, Mani S, et al. (2009) Anaphylaxis to gadolinium radiocontrast: a case report and review of the literature. J La State Med Soc 161: 282–284.
16. Raisch DW, Garg V, Arabyat R, et al. (2014) Anaphylaxis associated with gadolinium-based contrast agents: Data from the food and drug administration’s adverse event reporting system and review of case reports in the literature. Expert Opin Drug Saf 13: 15–23.
17. Franckenberg S, Berger F, Schaeerli S, et al. (2018) Fatal anaphylactic reaction to intravenous gadobutrol, a gadolinium-based MRI contrast agent. Radiol Case Rep 13: 299–301.
18. Jung JW, Kangand HR, Kim MH, et al. (2012) Immediate hypersensitivity reaction to gadolinium-based MR contrast media. *Radiology* 264: 414–422.
19. Morzycki A, Bhatia A, Murphy KJ (2017) Adverse reactions to contrast material: a Canadian update. *Can Assoc Radiol J* 68: 187–193.
20. Behzadi AH, Farooq Z, Newhouse JH, et al. (2018) MRI and CT contrast media extravasation a systematic review. *Medicine* 97: e0055.
21. Varela DC, Sepulveda P, Prieto J, et al. (2015) Extravasation of intravenous contrast media: What every radiologist should know. *Rev Chil Radiol* 21: 151–157.
22. Blasco-Perrin H, Glaser B, Pienkowski M, et al. (2013) Gadolinium induced recurrent acute pancreatitis. *Pancreatology* 13: 88–89.
23. Unal O, Arslan H (1999) Cardiac arrest caused by IV gadopentetate dimeglumin. *Am J Roentgenol* 172: 1141.
24. US Food and Drug Administration (2017) *Medical Imaging Drugs Advisory Committee Meeting*, FDA briefing document: Gadolinium retention after gadolinium based contrast magnetic resonance imaging in patients with normal renal function.
25. Maramattom BV, Manno EM, Wijdicks EFM, et al. (2005) Gadolinium encephalopathy in a patient with renal failure. *Neurology* 64: 1276–1278.
26. Hui FK, Mullins M (2009) Persistence of gadolinium contrast enhancement in CSF: A possible harbinger of gadolinium neurotoxicity? *Am J Neuroradiol* 30: e1.
27. Kim SH, Jo EJ, Kim MY, et al. (2013) Clinical value of radiocontrast media skin tests as a prescreening and diagnostic tool in hypersensitivity reactions. *Ann Allergy Asthma Immunol* 110: 258–262.
28. Shellock FG, Kanal E (1999) Safety of magnetic resonance imaging contrast agents. *J Magn Res Im* 10: 477–484.
29. Grobner T (2006) Gadolinium-a specific trigger for the development of nephrogen fibrosing dermotrophy and nephrogenic systemic fibrosis? *Nephrol Dial Transpl* 21: 1104–1108.
30. Thomson LK, Thomson PC, Kingsmore DB, et al. (2015) Diagnosing nephrogenic systemic fibrosis in the post-FDA restriction era. *J Magn Res Imaging* 41: 1268–1271.
31. Larson KN, Gagnon AL, Darling MD, et al. (2015) Nephrogenic systemic fibrosis manifesting a decade after exposure to gadolinium. *JAMA Dermatol* 151: 1117–1120.
32. Bernstein EJ, Schmidt-Lauber C, Kay J (2012) Nephrogenic systemic fibrosis: a systemic fibrosing disease resulting from gadolinium exposure. *Best Pract Res Cl Rheumatol* 26: 489–503.
33. Sanyal S, Marckmann P, Scherer S, et al. (2011) Multiorgan gadolinium (Gd) deposition and fibrosis in a patient with nephrogenic systemic fibrosis-an autopsy-based review. *Nephrol Dial Transplant* 26: 3616–3626.
34. Kay J, Bazari H, Avery LL, et al. (2008) Case 6-2008: a 46-year-old woman with renal failure and stiffness of the joints and skin. *New Engl J Med* 358: 827–838.
35. Bhave G, Lewis JB, Chang SS (2008) Association of gadolinium based magnetic resonance imaging contrast agents and nephrogenic systemic fibrosis. *J Urol* 180: 830–835.
36. Cowper SE, Su LD, Bhawan J, et al. (2001) Nephrogenic fibrosing dermopathy. *Am J Dermatopath* 23: 383–393.
37. Cowper SE, Robin HS, Steinberg SM, et al. (2000) Scleromyxedema-like cutaneous disease in renal dialysis patients. *Lancet* 356: 1000–1001.
38. Weigle JP, Broome DR (2008) Nephrogenic systemic fibrosis: chronic imaging findings and review of the medical literature. *Skeletal Radiol* 37: 457–464.

39. Zou Z, Zhang HL, Roditi GH, et al. (2011) Nephrogenic systemic fibrosis: review of 370 biopsy-confirmed cases. *JACC: Cardiovasc Imaging* 4: 1206–1216.

40. Morris MF, Zhang Y, Zhang H, et al. (2009) Features of nephrogenic systemic fibrosis on radiology examinations. *Am J Roentgenol* 193: 61–69.

41. Tsushima Y, Kanal E, Thomsen HS (2010) Nephrogenic systemic fibrosis: risk factors suggested from Japanese published cases. *Brit J Radiol* 83: 590–595.

42. Thomsen HS, Morcos SK, Almén T, et al. (2013) Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR contrast medium safety committee guidelines. *Eur Radiol* 23: 307–318.

43. Mazhar SM, Shiehmorteza M, Kohl CA, et al. (2009) Nephrogenic systemic fibrosis in liver disease: a systematic review. *J Magn Reson Imaging* 30: 1313–1322.

44. Elmholdt TR, Jørgensen B, Ramsing M, et al. (2010) Two cases of nephrogenic systemic fibrosis after exposure to the macrocyclic compound gadobutrol. *NDT Plus* 3: 285–287.

45. Kay J (2008) Gadolinium and nephrogenic systemic fibrosis: The evidence of things not seen. *Clev Clin J Med* 75: 112.

46. Todd DJ, Kay J (2008) Nephrogenic systemic fibrosis: an epidemic of gadolinium toxicity. *Curr Rheumatol Rep* 10: 195–204.

47. Sieber MA, Lengsfeld P, Frenzel T, et al. (2008) Preclinical investigation to compare different gadolinium- based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. *Eur Radiol* 18: 2164–2173.

48. Semelka RC, Prybylski JP, Ramalho M (2019) Influence of excess ligand on nephrogenic systemic fibrosis associated with nonionic, linear gadolinium-based contrast agents. *Magn Res Imaging* 58: 174–178.

49. US Food and Drug Administration (2007) FDA request boxes warning for contrast agents used to improve MRI images. Available from: http://wayback.archive-it.org/7993/20170112033008/http://www.fda.gov/NewsEvents/Newsrooms/PressAnnouncements/2007/ucm108919.htm

50. Khawaja AZ, Cassidy DB, Al Shakarchi J, et al. (2015) Revisiting the risks of MRI with Gadolinium based contrast agents: review of literature and guidelines. *Insights Imaging* 6: 553–558.

51. Canga A, Kislikova M, Martínez-Gálvez M, et al. (2014) Renal function, nephrogenic systemic fibrosis and other adverse reactions associated with gadolinium-based contrast media. *Nefrologia* 34: 428–438.

52. Martin DR, Krishnamoorthy SK, Kalb B, et al. (2010) Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast-enhanced MRI protocols. *J Magn Reson Imaging* 31: 440–446.

53. Altun E, Martin DR, Wertman R, et al. (2009) Nephrogenic systemic fibrosis: Change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy— report from two US universities. *Radiology* 253: 689–696.

54. Xia D, Davis RL, Crawford JA, et al. (2010) Gadolinium released from MR contrast agents is deposited in brain tumors: in situ demonstration using scanning electron microscopy with energy dispersive X-ray spectroscopy. *Acta Radiol* 51: 1126–1136.
55. Kanda T, Ishii K, Kawaguchi H, et al. (2014) High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: Relationship with increasing cumulative dose of a gadolinium based contrast material. Radiology 270: 834–841.
56. McDonald RJ, McDonald JS, Kallmes DF, et al. (2015) Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology 275: 772–782.
57. Olchowy C, Cebulski K, Łasecki M, et al. (2017) The presence of the gadolinium-based contrast agent depositions in the brain and symptoms of gadolinium neurotoxicity-a systematic review. PLoS One 12: e0171704.
58. Pullicino R, Radon M, Biswas S, et al. (2018) A review of the current evidence on gadolinium deposition in the brain. Clin Neuroradiol 28: 159–169.
59. Gianolio E, Gregorio ED, Aime S (2019) Chemical insights into the issues of Gd retention in the brain and other tissues upon the administration of Gd-containing MRI contrast agents. Eur J Inorg Chem 2019: 137–151.
60. Kanda T, Osawa M, Oba H, et al. (2015) High signal intensity in dentate nucleus on unenhanced T1-weighted MR images: association with linear versus macrocyclic gadolinium chelate administration. Radiology 275: 803–809.
61. Weberling LD, Kieslich PJ, Kickingereder P, et al. (2015) Increased signal intensity in the dentate nucleus on unenhanced T1-weighted images after gadobenate dimeglumine administration. Invest Radiol 50: 743–748.
62. Errante Y, Cirimele V, Mallio CA, et al. (2014) Progressive increase of T1 signal intensity of the dentate nucleus on unenhanced magnetic resonance images is associated with cumulative doses of intravenously administered gadodiamide in patients with normal renal function, suggesting dechelation. Invest Radiol 49: 685–690.
63. Zhang Y, Cao Y, Shih GL, et al. (2017) Extent of signal hyperintensity on unenhanced T1-weighted brain MR images after more than 35 administrations of linear gadolinium-based contrast agents. Radiology 282: 516–525.
64. Radbruch A, Weberling LD, Kieslich PJ, et al. (2015) Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent. Radiology 275: 783–791.
65. Malhotra A, LeSar B, Wu X, et al. (2018) Progressive T1 shortening of the dentate nucleus in patients with multiple sclerosis: Result of multiple administrations of linear gadolinium contrast agents versus intrinsic disease. Am J Roentgenol 211: 1099–1105.
66. Flood TF, Stence NV, Maloney JA, et al. (2017) Pediatric brain: Repeated exposure to linear gadolinium-based contrast material is associated with increased signal intensity at unenhanced T1-weighted MR imaging. Radiology 282: 222–228.
67. Adin ME, Kleinberg L, Vaidya D, et al. (2015) Hyperintense dentate nuclei on T1-weighted MRI: relation to repeat gadolinium administration. Am J Neuroradiol 36: 1859–1865.
68. Miller JH, Hu HH, Pokorney A, et al. (2015) MRI brain signal intensity changes of a child during the course of 35 gadolinium contrast examinations. Pediatrics 136: e1637–e1640.
69. Hu HH, Pokorney A, Towbin RB, et al. (2016) Increased signal intensities in the dentate nucleus and globus pallidus on unenhanced T1-weighted images: evidence in children undergoing multiple gadolinium MRI exams. Pediatr Radiol 46: 1590–1598.
70. Bae S, Lee H, Han K, et al. (2017) Gadolinium deposition in the brain: association with various GBCAs using a generalized additive model. Eur Radiol 27: 3353–3361.
71. Quattrocchi CC, Mallio CA, Errante Y, et al. (2015) Gadodiamide and dentate nucleus T1 hyperintensity in patients with meningioma evaluated by multiple follow-up contrast-enhanced magnetic resonance examinations with no systemic interval therapy. *Invest Radiol* 50: 470–472.
72. McDonald JS, McDonald RJ, Jentoft ME, et al. (2017) Intracranial gadolinium deposition following gadodiamide-enhanced magnetic resonance imaging in pediatric patients: a case-control study. *JAMA Pediatr* 171: 705–707.
73. Mallio CA, Vullo GL, Messina L, et al. (2020) Increased T1 signal intensity of the anterior pituitary gland on unenhanced magnetic resonance images after chronic exposure to gadodiamide. *Invest Radiol* 55: 25–29.
74. Gianolio E, Bardini P, Arena F, et al. (2017) Gadolinium retention in the rat brain: Assessment of the amounts of insoluble gadolinium-containing species and intact gadolinium complexes after repeated administration of gadolinium-based contrast agents. *Radiology* 285: 839–849.
75. Rasschaert M, Schroeder JA, Wu TD, et al. (2018) Multimodal imaging study of gadolinium presence in rat cerebellum: differences between Gd chelates, presence in the Virchow-Robin space, association with lipofuscin, and hypotheses about distribution pathway. *Invest Radiol* 53: 518.
76. Radbruch A, Richter H, Fingerhu S, et al. (2019) Gadolinium deposition in the brain in a large animal model. Comparison of linear and macrocyclic gadolinium-based contrast agents. *Invest Radiol* 54: 531–536.
77. Boyken J, Frenzel T, Lohrke J, et al. (2018) Gadolinium accumulation in the deep cerebellar nuclei and globus palidus after exposure to linear but not macrocyclic gadolinium-based contrast agents in a retrospective pig study with high similarity to clinical conditions. *Invest Radiol* 53: 278–285.
78. Robert P, Violas X, Grand S, et al. (2016) Linear gadolinium-based contrast agents are associated with brain gadolinium retention in healthy rats. *Invest Radiol* 51: 73–82.
79. Strzeminska I, Factor C, Robert P, et al. (2020) Long-term evaluation of gadolinium retention in rat brain after single injection of a clinically relevant dose of gadolinium-based contrast agents. *Invest Radiol* 55: 138–143.
80. Radbruch A, Haase R, Kieslich PJ, et al. (2017) No signal intensity increase in the dentate nucleus on unenhanced T1-weighted MR images after more than 20 serial injections of macrocyclic gadolinium-based contrast agents. *Radiology* 282: 699–707.
81. Radbruch A, Haase R, Kickingereder P, et al. (2017) Pediatric brain: no increased signal intensity in the dentate nucleus on unenhanced T1-weighted MR images after consecutive exposure to a macrocyclic gadolinium-based contrast agent. *Radiology* 283: 828–836.
82. Tibussek D, Rademacher C, Caspers J, et al. (2007) Gadolinium brain deposition after macrocyclic gadolinium administration: a pediatric case-control study. *Radiology* 285: 223–230.
83. Schneider GK, Stroeder J, Roditi G, et al. (2017) T1 signal measurements in pediatric brain: findings after multiple exposures to gadobenate dimeglumine for imaging of non neurologic disease. *Am J Neuroradiol* 38: 1799–1806.
84. Conte G, Preda L, Cocorocchio E, et al. (2017) Signal intensity change on unenhanced T1-weighted images in dentate nucleus and globus pallidus after multiple administrations of gadoxetate disodium: an intraindividual comparative study. *Eur Radiol* 27: 4372–4378.
85. Ryu YJ, Choi YH, Cheon J, et al. (2018) Pediatric brain: Gadolinium deposition in dentate nucleus and globus pallidus on unenhanced T1-weighted images is dependent on the type of contrast agent. *Invest Radiol* 53: 246–255.
86. Stanescu AL, Shaw DW, Murata N, et al. (2020) Brain tissue gadolinium retention in pediatric patients after contrast-enhanced magnetic resonance exams: pathological confirmation. *Pediatr Radiol* 50: 388–396.
87. Bjø rnerud A, Vatnehol SAS, Larsson C, et al. (2017) Signal enhancement of the dentate nucleus at unenhanced MR imaging after very high cumulative doses of the macrocyclic gadolinium-based contrast agent gadobutrol: an observational study. *Radiology* 285: 434–444.
88. Splendiani A, Perri M, Marsecano C, et al. (2018) Effects of serial macrocyclic based contrast materials gadoterate meglumine and gadobutrol administrations on gadolinium related dentate nuclei signal increases in unenhanced t1-weighted brain: a retrospective study in 158 multiple sclerosis (MS) patients. *Radiol Med* 123: 125–134.
89. Stojanov DA, Aracki-Trenkic A, Vojinovic S, et al. (2016) Increasing signal intensity within the dentate nucleus and globus pallidus on unenhanced T1W magnetic resonance images in patients with relapsing remitting multiple sclerosis: Correlation with cumulative dose of a macrocyclic gadolinium-based contrast agent, gadobutrol. *Eur Radiol* 26: 807–815.
90. Tedeschi E, Palma G, Canna A, et al. (2016) In vivo dentate nucleus MRI relaxometry correlates with previous administration of gadolinium-based contrast agents. *Eur Radiol* 26: 4577–4584.
91. Lattanzio SM, Imbesi F (2020) Fibromyalgia associated with repeated gadolinium contrast-enhanced MRI examinations. *Radiol Case Rep* 15: 534–541.
92. Roberts DR, Welsh CA, LeBel DP, et al. (2017) Distribution map of gadolinium deposition within the cerebellum following GBCA administration. *Neurology* 88: 1206–1208.
93. Gibby WA, Gibby KA, Gibby WA (2004) Comparison of Gd-DTPA-BMA (Omniscan) versus Gd-HPDO3A (ProHance) retention in human bone tissue by inductively coupled plasma atomic emission spectroscopy. *Invest Radiol* 39: 138–142.
94. White GW, Gibby WA, Tweedle MF (2006) Comparison of Gd(DTPA-BMA)(Omniscan) versus Gd(HPDO3A)(ProHance) relative to gadolinium retention in human bone tissue by inductively coupled mass spectroscopy. *Invest Radiol* 41: 272–278.
95. Darrah TH, Prutsman-Pfeiffer JJ, Poreda RJ, et al. (2009) Incorporation of excess gadolinium into human bone from medical contrast agents. *Metallomics* 1: 479–488.
96. Murata N, Gonzalez-Cuyar LF, Murata K, et al. (2016) Macrocyclic and other non–group 1 gadolinium contrast agents deposit low levels of gadolinium in brain and bone tissue: Preliminary results from 9 patients with normal renal function. *Invest Radiol* 51: 447–53.
97. Lord ML, Chettle DR, Gräfe JL, et al. (2018) Observed deposition of gadolinium in bone using a new noninvasive in vivo biomedical device: Results of a small pilot feasibility study. *Radiology* 287: 96–103.
98. Turyanskaya A, Rauwol M, Pichler V, et al. (2020) Detection and imaging of gadolinium accumulation inhuman bone tissue by micro- and submicro-XRF. *Sci Rep* 10: 6301.
99. Vidaud C, Bourgeois D, Meyer D (2012) Bone as target organ for metals: the case of f-elements. *Chem Res Toxicol* 25: 1161–1175.
100. Gräfe JL, McNeill FE (2018) Measurement of gadolinium retention: current status and review from an applied radiation physics perspective. *Physiol Meas* 39: 06TR01.
101. Hasegawa M, Duncan BR, Marshall DA, et al. (2020) Human hair as a possible surrogate marker of retained tissue gadolinium. A pilot autopsy study correlating gadolinium concentrations in hair with brain and other tissues among decedents who received gadolinium-based contrast agents. *Invest Radiol* 55: 636–642.

102. Saussereau E, Lacroix C, Cattaneo A, et al. (2008) Hair and fingernail gadolinium ICP-MS contents in an overdose case associated with nephrogenic systemic fibrosis. *Forensic Sci Int* 176: 54–57.

103. US Food and Drug Administration, 5-18, 2015. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-evaluating-risk-brain-deposits-repeated-use-gadolinium-based.

104. EMA/625317/2017. EMA's final opinion confirms restrictions on use of linear gadolinium agents in body scans. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/gadolinium__contrast__agents__31/European_Commission_final_decision/WC500240575.pdf.

105. Lancelot E, Desché P (2020) Gadolinium retention as a safety signal: experience of a manufacturer. *Invest Radiol* 55: 20–24.

106. PMDA, Revision of Precautions, Gadodiamide hydrate Meglumine gadopentetate, 2017. Available from: http://www.pmda.go.jp/files/000221377.pdf.

107. PMDA, Revision of Precautions, Gadoterate sodium, Gadoteridol, Meglumine gadoterate, Gadobutrol, 2017. Available from: http://www.pmda.go.jp/files/000221376.pdf.

108. Kanda T, Nakai Y, Hagiwara A, et al. (2017) Distribution and chemical forms of gadolinium in the brain: a review. *Br J Radiol* 90: 20170115.

109. Bayer, Bracco Diagnostics, GE Healthcare, Guerbet. Important drug warning for all gadolinium-based contrast agents [Dear health care provider letter] (2018). Available from: https://www.guerbet.com/media/uh4h4kon/dhcp-letter-05-02-2018-signed.pdf.

110. Harvey HB, Gowda V, Cheng G (2019) Gadolinium deposition disease: a new risk management threat. *J Am Coll Radiol* 17: 546–550.

111. Semelka RC, Commander CW, Jay M, et al. (2016) Presumed gadolinium toxicity in subjects with normal renal function a report of 4 cases. *Invest Radiol* 51: 661–665.

112. Semelka RC, Ramalho M, Jay M (2016) Summary of special issue on gadolinium bioeffects and toxicity with a look to the future. *Magn Reson Imaging* 34: 1399–1401.

113. US Food and Drug Administration (2017) *Medical Imaging Drugs Advisory Committee Meeting*, FDA briefing document: Gadolinium retention after gadolinium-based contrast magnetic resonance imaging in patients with normal renal function, 27–28.

114. Burke LMB, Ramalho M, AlObaidy M, et al. (2016) Self-reported gadolinium toxicity: A survey of patients with chronic symptoms. *Magn Reson Imaging* 34: 1078–1080.

115. Semelka RC, Ramalho J, Vakharia A, et al. (2016) Gadolinium deposition disease: initial description of a disease that has been around for a while: a family of disorders. *Magn Res Imaging* 34: 1383–1390.

116. Roberts DR, Lindhorst SM, Welsh CT, et al. (2016) High levels of gadolinium deposition in the skin of a patient with normal renal function. *Invest Radiol* 51: 280–289.

117. Barbieri S, Schroeder C, Froehlich JM, et al. (2016) High signal intensity in dentate nucleus and globus pallidus on unenhanced T1-weighted MR images in three patients with impaired renal function and vascular calcification. *Contrast Media Mol Imaging* 11: 245–250.
118. Swaminathan S (2016) Gadolinium toxicity: iron and ferroportin as central targets. *Magn Reson Imaging* 34: 1373–1376.

119. Di Gregorio ED, Furlan C, Atlante S, et al. (2020) Gadolinium retention in erythrocytes and leukocytes from human and murine blood upon treatment with gadolinium-based contrast agents for magnetic resonance imaging. *Invest Radiol* 55: 30–37.

120. Di Gregorio E, Ferrauto G, Furlan C, et al. (2018) The issue of gadolinium retained in tissue. *Invest Radiol* 53: 167–172.

121. Kartamihardja AAP, Hanaoka H, Andriana P, et al. (2019) Quantitative analysis of Gd in the protein content of the brain following single injection of gadolinium-based contrast agents (GBCAs) by size exclusion chromatography. *Br J Radiol* 92: 20190062.

122. Newton BB, Jimenez SA (2009) Mechanism of NSF: New evidence challenging the prevailing theory. *J Magn Reson Imaging* 30: 1277–1283.

123. Taoka T, Jost G, Frenzel T, et al. (2018) Impact of the glymphatic system on the kinetic and distribution of gadodiamide in rat brain. *Invest Radiol* 53: 529–534.

124. Nehra AK, McDonald RJ, Bluhm AM, et al. (2018) Accumulation of gadolinium in human cerebrospinal fluid after gadobutrol-enhanced MR imaging: a prospective observational cohort study. *Radiology* 288: 416–423.

125. McDonald RJ, Levine D, Weinreb J, et al. (2018) Gadolinium retention: A research roadmap from the 2018 NIH/ACR/RSNA workshop on gadolinium chelates. *Radiology* 289: 517–534.

126. Le Fur M, Caravan P (2019) The biological fate of gadolinium-based MRI contrast agents: a call to action for bioinorganic chemists. *Metallomics* 11: 240–254.

127. Tweedle MF (2016) Gadolinium deposition: Is it chelated or dissociated gadolinium? How can we tell? *Magn Res Imaging* 34: 1377–1382.

128. Kiviniemi A, Gardberg M, Ek P, et al. (2019) Gadolinium retention in gliomas and adjacent normal brain tissue: association with tumor contrast enhancement and linear/macroyclic agents. *Neuroradiology* 61: 535–544.

129. Kanda T, Fukusato T, Matsuda M, et al. (2015) Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy. *Radiology* 276: 228–232.

130. Herculano-Houzel S (2009) The human brain in numbers: a linearly scaled-up primate brain. *Front Hum Neurosci* 3: 31.

131. Popescu BFG, Robinson CA, Rajput A, et al. (2009) Iron, copper, and zinc distribution of the cerebellum. *Cerebellum* 8: 74–79.

132. Kromrey ML, Liedtke KR, Ittermann T, et al. (2017) Intravenous injection of gadobutrol in an epidemiological study group did not lead to a difference in relative signal intensities of certain brain structures after 5 years. *Eur Radiol* 27: 772–777.

133. Staks T, Schuhmann-Giampieri G, Frenzel T, et al. (1994) Pharmacokinetics, dose proportionality and tolerability of gadobutrol after single intravenous injection in healthy volunteers. *Invest Radiol* 29: 709–715.

134. Gutierrez JE, Rosenberg M, Duhaney M, et al. (2015) Phase 3 efficacy and safety trial of gadobutrol, a 1.0 molar macrocyclic MR imaging contrast agent, in patients referred for contrast-enhanced MR imaging of the central nervous system. *J Magn Reson Imaging* 41: 788–796.
135. Kuwatsuru R, Takahashi S, Umeoka S, et al. (2015) A multicenter, randomized, controlled, single-blind comparison phase III study to determine the efficacy and safety of gadobutrol 1.0 M versus gadopentetate dimeglumine following single injection in patients referred for contrast-enhanced MRI of the body regions or extremities. J Magn Reson Imaging 41: 404–413.

136. Liang Z, Ma L, Wang D, et al. (2012) Efficacy and safety of gadobutrol (1.0 M) versus gadopentetate dimeglumine (0.5 M) for enhanced MRI of CNS lesions: A phase III, multicenter, single-blind, randomized study in Chinese patients. Mag Res Insights 5: MRI–S9348.

137. Naito S, Tazaki H, Okamoto T, et al. (2017) Comparison of nephrotoxicity between two gadolinium-contrasts, gadodiamide and gadopentetate in patients with mildly diminished renal failure. J Toxicol Sci 42: 379–384.

138. Semelka RC, Hernandes MA, Stallings CG, et al. (2013) Objective evaluation of acute adverse events and image quality of gadolinium-based contrast agents (gadobutrol and gadobenate dimeglumine) by blinded evaluation. Pilot study. Magn Reson Imaging 31: 96–101.

139. Tanaka A, Masumoto T, Yamada H, et al. (2016) A Japanese, multicenter, open-label, phase 3 study to investigate the safety and efficacy of gadobutrol for contrast-enhanced MR imaging of the central nervous system. Magn Reson Med Sci 15: 227–236.

140. Zech CJ, Schwenke C, Endrikat J (2019) Diagnostic efficacy and safety of gadoxetate disodium vs gadobenate dimeglumine in patients with known or suspected focal liver lesions: Results of a clinical phase III study. Magn Reson Insight 12: 1178623X19827976.

141. Tweedle MF, Wedeking P, Kumar K (1995) Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats. Invest Radiol 30: 372–380.

142. Rocklage SM, Worah D, Kim SH (1991) Metal ion release from paramagnetic chelates: what is tolerable? Magn Reson Med 22: 216–221.

143. Khairinisa MA, Takatsuru Y, Amano I, et al. (2018) The effect of perinatal gadolinium-based contrast agents. Invest Radiol 53: 110–118.

144. Ray JG, Vermeulen MJ, Bharatha A, et al. (2016) Association between MRI exposure during pregnancy and fetal and childhood outcomes. JAMA 316: 952–961.

145. Runge VM, Kuehl TJ, Jackson CB, et al. (2005) Subchronic toxicity of the gadolinium chelates. Acad Radiol 12: S6–S9.

146. Alkhunizi SM, Fakhoury M, Abou-Kheir W, et al. (2020) Gadolinium retention in the central and peripheral nervous system: implications for pain, cognition, and neurogenesis. Radiology 297: 407–416.

147. Wang S, Hesse B, Roman M, et al. (2019) Increased retention of gadolinium in the inflamed brain after repeated administration of gadopentetate dimeglumine. Invest Radiol 54: 617–626.

148. Reimer P, Vossenrich R (2008) Off-label use of contrast agents. Eur Radiol 18: 1096–1101.

149. Essig M, Shiroishi MS, Nguyen TB, et al. (2013) Perfusion MRI: The five most frequently asked technical questions. Am J Roentgenol 200: 24–34.

150. Wolansky LJ, Cadavid D, Punia V, et al. (2015) Hypophosphatemia is associated with the serial administration of triple-dose gadolinium to patients for brain MRI. J Neuroimaging 25: 379–383.

151. Essig M, Giesel E, Le-Huu M, et al. (2004) Perfusion MRI in CNS disease: current concepts. Neuroradiology 46: S201–S207.
152. Lee JY, Park JE, Kim HS, et al. (2017) Up to 52 administrations of macrocyclic ionic MR contrast agent are not associated with intracranial gadolinium deposition: multifactorial analysis in 385 patients. PloS One 12: e0183916.

153. Ng KH, Ahmad AC, Nizam M, et al. (2003) Magnetic resonance imaging: Health effects and safety, Proceedings of the international conference on non-ionizing radiation at UNITEN, Electromagnetic Fields and our Health.

154. Cho S, Lee Y, Choi YJ, et al. (2014) Enhanced cytotoxic and genotoxic effects of gadolinium following ELF-EMF irradiation in human lymphocytes. Drug Chem Toxicol 37: 440–447.

155. Sadiq S, Ghazala Z, Chowdhury A, et al. (2012) Metal toxicity at the synapse: presynaptic, postsynaptic, and long-term effects. J Toxicol 2012: 132671.

156. Food U S, Drug Administration, Safety Announcement 2017. Available from: https://www.fda.gov/media/109825/download.

157. Veiga M, Mattiauzzi P, de Goisc JS, et al. (2020) Presence of other rare earth metals in gadolinium-based contrast agents. Talanta 216: 120940.

158. Parfrey P (2005) The clinical epidemiology of contrast-induced nephropathy. Cardiovasc Intervent Radiol 28: S3–S11.

159. Karcaaltincaba M, Oguz B, Haliloglu M (2009) Current status of contrast-induced nephropathy and nephrogenic systemic fibrosis in children. Pediatr Radiol 39 (Suppl 3): S382–S384.

160. Kulaksiz S, Bau M (2011) Anthropogenic gadolinium as a micro-contaminant in tap water used as drinking water in urban areas and megacities. Appl Geochem 26: 1877–1885.

161. Hatje V, Bruland KW, Flegal AR (2016) Increases in anthropogenic gadolinium anomalies and rare earth element concentrations in San Francisco bay over a 20 year record. Environ Sci Technol 50: 4159–4168.

162. Rabiet M, Brissaud F, Seidel JL, et al. (2009) Positive gadolinium anomalies in wastewater treatment plant effluents and aquatic environment in the Hérault watershed (South France). Chemosphere 75: 1057–1064.

163. Chen Y, Cao XD, Lu Y, et al. (2000) Effects of rare earth metal ions and their EDTA complexes on antioxidant enzymes of fish liver. B Environ Contam Tox 65: 357–365.

164. Henriques B, Coppola F, Monteiro R, et al. (2019) Toxicological assessment of anthropogenic gadolinium in seawater: Biochemical effects in mussels mytilus galloprovincialis. Sci Total Environ 664: 626–634.

165. Hanana H, Turcotte P, André C, et al. (2017) Comparative study of the effects of gadolinium chloride and gadolinium-based magnetic resonance imaging contrast agent on freshwater mussel, dreissena polymorpha. Chemosphere 181: 197–207.

166. Martino C, Costa C, Roccheria MC, et al. (2018) Gadolinium perturbs expression of skeletogenic genes, calcium uptake and larval development in phylogenetically distant sea urchin species. Aquat Toxicol 194: 57–66.

167. Schmidt K, Bau M, Merschel G, et al. (2019) Anthropogenic gadolinium in tap water and in tap-based beverages from fast-food franchises in six major cities in Germany. Sci Total Environ 687: 1401–1408.